Research Disciplines
Socio-Economic Objectives

These are the most recent publications associated with this author. To see a detailed profile of all publications stored at JCU, visit ResearchOnline@JCU. Hover over Altmetrics badges to see social impact.

Journal Articles

ResearchOnline@JCU stores 32+ research outputs authored by Prof Alan Nimmo from 2000 onwards.

Current Funding

Current and recent Research Funding to JCU is shown by funding source and project.

Commonwealth Department of Health - Medical Research Future Fund - Cardiovascular Health

The SPRINTS Project: Stroke - Prevention of Reperfusion

Indicative Funding
$797,893 over 4 years (administered by University of Adelaide)
Stroke represents a major clinical and social burden, being a leading cause of death, but also adult disability and dementia. The SPRINTS Project represents a novel therapeutic approach to significantly improve patient outcomes following an ischaemic stroke. The project represents a low-risk strategy to deliver a novel therapeutic agent to clinical trial for this area of high medical need. Through direct engagement with our world-leading clinical team, as well as with patient and consumer advocates, we expect the SPRINTS project to improve patient outcomes from acute stroke events, providing direct benefits to Australia and Australians.
Renee Turner, Henry Ma, Alan Nimmo, Connie Wong, James Bourne, Nicholas Veldhuis, Jonathan Baell, Michelle McIntosh and Daniel Poole (University of Adelaide, Monash Health, Academy and Monash University)
Ischaemic stroke; Neuroinflammation; Reperfusion iINjury; Blood brain barrier; NK1- Recepter Antagonist; Haemorrhagic transformation

National Health & Medical Research Council - Development Grant

Preventing reperfusion injury in stroke with an acutely dosed NK1R antagonist prodrug

Indicative Funding
$20,000 over 2 years (administered by Monash University)
Stroke represents a major clinical and societal burden, being a leading cause of adult disability, dementia, and death. The aim is to develop a novel therapeutic approach to significantly improve patient outcomes following an ischaemic stroke through the development of a novel therapeutic agent that can be delivered in conjunction with current approved reperfusion therapy. The plan involves critical de-risking efforts to deliver a low-risk strategy for progression to clinical trial. The plan focuses on the development of prodrugs of the NK1R antagonist, befetupitant, appropriately soluble for i.v. dosing, and accompanied by preclinical PK-PD data for formal, rapid preclinical development.
Jonathan Baell, Alan Nimmo, Susan Charman, Connie Wong and Nicholas Veldhuis (Monash University and Academy)
Stroke; Reperfusion Injury; Tachykinin NK1 receptor; Intravenous formulation; NK1 receptor antagonist; Prodrug development

Advisory Accreditation: I can be on your Advisory Panel as a Primary or Secondary Advisor.

These Higher Degree Research projects are either current or by students who have completed their studies within the past 5 years at JCU. Linked titles show theses available within ResearchOnline@JCU.

  • Comparison of Efficacy of Local and Systemic Antibiotics in Combination with Scaling and Root Planning in Patients with Moderate to Severe Periodontal Disease. A Clinical Study (PhD , Secondary Advisor)

The map shows research collaborations by institution from the past 7 years.
Note: Map points are indicative of the countries or states that institutions are associated with.

  • 5+ collaborations
  • 4 collaborations
  • 3 collaborations
  • 2 collaborations
  • 1 collaboration
  • Indicates the Tropics (Torrid Zone)

Connect with me
Share my profile
Share my profile:

Advisory Accreditation
Primary Advisor
Find me on…
Icon for Scopus Author page